Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics

Axsome Therapeutics, Inc. (AXSM): $75.19

1.01 (+1.36%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

AXSM Price/Volume Stats

Current price $75.19 52-week high $98.40
Prev. close $74.18 52-week low $55.02
Day low $74.19 Volume 377,200
Day high $75.41 Avg. volume 686,841
50-day MA $74.28 Dividend yield N/A
200-day MA $74.89 Market Cap 3.57B

AXSM Stock Price Chart Interactive Chart >


Axsome Therapeutics, Inc. (AXSM) Company Bio


Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.


AXSM Latest News Stream


Event/Time News Detail
Loading, please wait...

AXSM Latest Social Stream


Loading social stream, please wait...

View Full AXSM Social Stream

Latest AXSM News From Around the Web

Below are the latest news stories about AXSOME THERAPEUTICS INC that investors may wish to consider to help them evaluate AXSM as an investment opportunity.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity exploring reduction of depressive symptoms regardless of a patient’s interest-activity symptom severity NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (C

Yahoo | December 11, 2023

3 Unstoppable Stocks to Buy Right Now

Here's why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Axsome Therapeutics): One promising growth stock that investors may be overlooking today is Axsome Therapeutics. With a market capitalization of around $3.2 billion, this is still a fairly small biotech stock for investors to load up on before it gets much bigger.

Yahoo | December 10, 2023

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m. – 10 a.m. Eastern Time to provide an update on solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and trace amine-associated receptor 1 (TAAR1) agonist. At the event, invited ph

Yahoo | December 7, 2023

11 Best Upside Stocks To Buy Right Now

In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […]

Yahoo | November 27, 2023

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on December 7 from 8 a.m. - 10 a.m. Eastern Time to provide investors an update on its development programs for solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1)

Yahoo | November 22, 2023

Read More 'AXSM' Stories Here

AXSM Price Returns

1-mo 4.85%
3-mo -9.36%
6-mo 11.48%
1-year N/A
3-year 23.85%
5-year 207.90%
YTD -5.53%
2023 3.19%
2022 104.16%
2021 -53.63%
2020 -21.18%
2019 3,565.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!